Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Innovotech Inc. (V:IOT)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 2011 94 St NW Suite 101
EDMONTON AB T6N 1H1
Tel: N/A
Website: https://innovotech.ca
IR: See website
Key People
James Timourian
Chairman of the Board, President, Chief Executive Officer, Company Secretary
Alan C. Savage
Chief Financial Officer, Director
 
Business Overview
Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.
Financial Overview
For the nine months ended 30 September 2023, Innovotech Inc revenues decreased 4% to C$842K. Net loss increased from C$53K to C$128K. Revenues reflect Rest Of World segment decrease of 18% to C$88K, Canada segment decrease of 36% to C$20K. Higher net loss reflects General and Administrative increase of 14% to C$704K (expense), Sales and Marketing increase from C$1K to C$24K (expense).
Employees: 16 as of Mar 13, 2012
Reporting Currency: Canadian Dollars
Enterprise value: $3.78M as of Sep 30, 2023
Annual revenue (TTM): $1.09M as of Sep 30, 2023
EBITDA (TTM): -$0.18M as of Sep 30, 2023
Net annual income (TTM): -$0.21M as of Sep 30, 2023
Free cash flow (TTM): -$0.26M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 39,003,612 as of Feb 6, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization